Shots:
- Novo Nordisk has partnered with Vivtex to develop next-generation oral biologics for obesity, diabetes, & related comorbidities, leveraging Vivtex’s GI screening & formulation platform
- Vivtex will license select oral drug-delivery techs to Novo, which will lead global development, regulatory, manufacturing & commercialization, while Vivtex will receive an upfront, research funding, & milestone payments totalling ~$2.1B, with tiered royalties
- Vivtex’s platform integrates proprietary GI screening assays, advanced drug-delivery technologies, & AI-driven computational modeling to optimize oral biologics, aiming to deliver high bioavailability and consistent, reliable in-human performanceÂ
Ref: Novo Nordisk | Image: Novo Nordisk & Vivtex | Press Release
Related News: Novo Nordisk Reports EC Approval of Higher Injectable Wegovy Dose for Weight Management
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
